The data demonstrate faster progression of SSc in autoantibody–positive patients, particularly in those with preclinical internal organ involvement at baseline, than in autoantibody–negative patients. PubMed, Arthritis Care Res (Hoboken), 2014 Feb 10. (Also see: Scleroderma Autoantibodies and Capillaroscopy)
This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.